Monopar Therapeutics Inc. (MNPR)
NASDAQ (CM) NASDAQ (CM) Primary 
XSTU 
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor patients is likely to respond to MNPR-101-Lu in a phase 1 study. The global solid tumor cancer treatment market size is projected to hit around $532.42 billion by 2032; uPAR expression is high in a variety of types of solid tumors.
3 Momentum Stocks Soaring Into 2025 and Beyond
Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement than it does the fundamentals of a company.
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus
Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase 3 asset for Wilson disease, diversifies MNPR's portfolio but does not directly complement its oncology focus.
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before falling to around $17 now. The 6x rise in a matter of days can be attributed to a major licensing development for Monopar.
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics NASDAQ: MNPR saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000.
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
